Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs Gilead Sciences, Inc. — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.79, while Gilead Sciences, Inc. trades at $136.03 (market cap $163.51B). The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF pays none. Which is the better fit depends on your goals.
| FLRN | GILD | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $30.86 | $155.80 |
52-Week Low | $30.65 | $108.22 |
Market Cap | — | $163.51B |
Enterprise Value | — | $178.05B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLRN trades at $30.79 with no price movement in the last 24 hours. The technical picture shows a bearish trend with moving averages indicating selling pressure, though oscillators are neutral. Key financial ratios including P/E, P/S, and ROE are unavailable in the current data. Recent corporate actions include three dividend payments of $0.11 each scheduled for mid-2026, suggesting management's commitment to shareholder returns despite the current technical weakness.
The outlook for FLRN appears cautious with bearish technical signals dominating. The stock faces headwinds from the current market environment where inflation concerns are driving investors toward inflation-protected assets. Investment opportunities exist in the consistent dividend payments, but risks include the overall bearish technical setup and potential pressure from rising interest rates that could impact stock valuations broadly.
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
